secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001437749-24-026567
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q2 2024 net loss $7.9M; cash $6.2M; OLE topline data expected Q4 2024
----------------------------------------------------------------------------

- Net loss of $7.9M ($0.26/sh) vs $11.7M ($0.52/sh) in Q2 2023; six-month loss $15.3M ($0.51/sh).
- Cash $6.2M at June 30, 2024, down from $23.4M at Dec 31, 2023.
- Topline data from 1-year OLE trial in schizophrenia expected Q4 2024; registrational RECOVER-2 trial to start Q3 2024.
- U.S. patent granted for brilaroxazine in IPF; European patent for pulmonary hypertension; both received Orphan Drug Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924026567/0001437749-24-026567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924026567/rvph20240807_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer